Rheumatology

Five things for pharma marketers to know: Thursday, May 21

Five things for pharma marketers to know: Thursday, May 21

By

CVS will buy institutional pharmacy Omnicare in a $12.7-billion deal; ProPublica says the FDA and GlaxoSmithKline failed to protect patients from misusing Advair; Regeneron and Sanofi expect to file RA drug sarilumab with the FDA in the fourth quarter of this year

Amgen, Novartis, BMS map future

Amgen, Novartis, BMS map future

By

Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.

Abandonment rates indicate room in the anti-TNF market

Abandonment rates indicate room in the anti-TNF market

By

Swedish researchers found rheumatoid arthritis patients tend to drop their first anti-TNF treatment.

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

By

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

FDA approves oral psoriatic arthritis drug

FDA approves oral psoriatic arthritis drug

By

Celgene is looking to market the $22,500-a-year-drug as a pre-biologic, which means jumping ahead of rivals like Enbrel and Humira.

Big Pharma puts $250M towards disease collaboration

Ten pharma companies will share money and biomarker research under an NIH collaboration.

Biogen Idec pursues anti-TNF biosimilars

Biogen Idec pursues anti-TNF biosimilars

By

Biogen Idec and JV partner Samsung are going into the biosimilars business.

Study says DPP-IV benefits may go beyond diabetes

Researchers say the drug class could be linked to a lower autoimmune risk among diabetics.

Passing Plavix shadow, BMS sees sales bump

Passing Plavix shadow, BMS sees sales bump

By

BMS is showing signs of emerging from the cliff, but doubt lingers on Eliquis's slow launch in a post-Plavix marketplace.

Xeljanz line extension could lift drug's profile

Xeljanz line extension could lift drug's profile

By

An analyst notes that early Phase III results in a psoriasis clinical trial could change the drug's efficacy profile. It could also fill out the financial potential of a standalone innovative unit, should Pfizer divide.

Rampant dissatisfaction with psoriasis drugs: study

Rampant dissatisfaction with psoriasis drugs: study

By

Sales may be rising, but a new study finds current psoriasis therapies leave room for improvement. Over half of patients said they want better options.

With RA indication, J&J's Simponi an up-and-comer

By

Analysts gave the infusion therapy a warm reception in RA, despite stiff competition in this category.

EU backs Remicade biosimilars; anti-TNFs at risk

By

CHMP recommended two Remicade biosimilars for approval. Its nod comes with an added shakeup: the European agency sanctioned the copies for indications beyond RA.

Sandoz readies Enbrel biosimilar for testing

By

The drug maker says it expects to use the Phase III clinical trial data to back applications in the EU and the US (when it gets a pathway setup).

Business briefs: Medscape, Livestrong, ACA, Lilly

Medscape asked and doctors shared what they hate about most medical apps, Livestrong merch hits the clearance rack, healthcare reform savings begin to surface, Lilly releases early RA drug trial results

Study shows old-school meds as effective as Enbrel

By

A cocktail of older meds works as well as Enbrel, a study found, but docs are already comfortable with prescribing the biologic and aren't likely to switch therapies.

Belushi, Savient observe Gout Awareness Day

By

The actor and patient heads up a roundtable posted on the advocacy site CreakyJoints.

Breakup, Xeljanz plans dominate Pfizer earnings call

By

Sales slipped 9% during the quarter, compared to the same period last year, but analysts zeroed in on if and when the company will split and how arthritis pill Xeljanz will tackle Europe.

AbbVie reports first-ever quarter, downplays Pfizer impact

By

Humira led in sales and the company told analysts Pfizer's Xeljanz setback in Europe won't alter its RA future all that much.

Europe halts Xeljanz progress

By

European regulators said they're not satisfied that the information they have on hand is enough to let the drug go forward.

Business Briefs: AstraZeneca, Amgen, BMS and Merck

AstraZeneca cuts a deal with OCB to test unnamed cancer drug; an Enbrel biosimilar launches in India; BMS and Santaris seal an mRNA tech deal; Merck expands its China presence; Alzheimer's advocacy group parents a spin-off.

The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters